Attention-Deficit/Hyperactivity Disorder (ADHD) is no longer considered a childhood-limited condition, with new data confirming significant diagnostic prevalence among adults worldwide. According to 2025 projections extrapolated from the latest Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report (MMWR) and CHADD analyses, approximately 16.13 million U.S. adults (6.2% of the adult population) and 404 million adults globally currently live with ADHD . Notably, over half (55.9%) received their diagnosis in adulthood, highlighting critical gaps in childhood identification .
Key U.S. Statistics from MMWR 2024 Report
- Age Disparity: 84.5% of diagnosed adults are under age 50 versus 51.2% in older cohorts
- Treatment Gaps: 36.5% receive no treatment despite diagnosis
- Medication Access Crisis: 71.5% of adults prescribed stimulants report difficulty filling prescriptions due to shortages
- Telehealth Adoption: 46% have utilized telehealth services for ADHD management
Global Prevalence and Treatment Patterns
| Region | Estimated ADHD Prevalence (Adults) | Primary Treatment Approaches |
|---|---|---|
| United States | 16.13 million (6.2%) | 50.4% medication, 35.2% combined therapy |
| Global Average | 404 million (4.4%) | Regional variations; non-stimulants gaining traction |
*Sources: MMWR 2024 ; Global extrapolations from Journal of Global Health
Non-Stimulant Medications: Addressing Shortages and Expanding Options
With ongoing stimulant shortages affecting 71.5% of U.S. patients , non-stimulant alternatives have seen increased adoption. Atomoxetine (Strattera) prescriptions have risen by approximately 18% since 2023 due to:
- No DEA Schedule classification reducing prescription barriers
- Lower abuse potential compared to stimulants
- 24-hour symptom coverage beneficial for working adults
Cost remains a significant factor in medication selection. Current pricing data shows:
- Brand-name Strattera: $553/month for 60mg capsules
- Generic atomoxetine: $469/month (15% savings)
Clinical Implications and Future Directions
“The sustained ADHD medication shortages constitute a public health emergency,” notes the editorial board of Shanghai Archives of Psychiatry. “Healthcare systems must prioritize both supply chain solutions and clinician education on non-stimulant alternatives to prevent treatment discontinuation.”
Upcoming APSARD adult ADHD guidelines (late 2025) are expected to standardize diagnostic protocols across specialties and expand non-pharmacological recommendations, including digital therapeutics and workplace accommodations .
Read Next:
- A Practical, Plain-English Guide to ADHD Medications (2025)
- Switching from Stimulants to Strattera: Step-by-Step
- Strattera
Explore current Strattera pricing options: See monthly cost analysis for brand and generic atomoxetine